We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EMR raised its 2025 sales growth forecast to 4%, up from the prior range of 1.5-3.5%.
Strong demand in power, LNG and life sciences is boosting EMR's process and hybrid industry sales.
The AspenTech acquisition expands EMR's automation reach and software-defined control capabilities.
Emerson Electric Co. (EMR - Free Report) is poised to gain from healthy demand across the majority of its end markets. Solid demand in the process and hybrid industries is boosting underlying sales. EMR’s underlying sales increased 2% year over year in the first six months of fiscal 2025 (ended March 2025). The company expects sales in the process and hybrid industry to grow in mid-single digits in the second half of fiscal 2025, driven by strength in the life sciences, energy, liquefied natural gas (LNG) and power end markets.
Strong momentum in the Intelligent Devices and Software and Control segments is driving Emerson’s performance. The Intelligent Devices segment is seeing strength in the Final Control business, fueled by robust demand in power end markets. The Measurement & Analytical business is benefiting from robust growth across the Asia, the Middle East and Africa regions. In the Software & Control segment, solid growth at AspenTech and strength in the power and process end markets are boosting the Control Systems & Software business’ performance.
Given the strength across EMR’s end markets, it has updated its outlook for fiscal 2025 (ending September 2025). Emerson now expects net sales to increase approximately 4% year over year compared with 1.5-3.5% anticipated earlier. Underlying sales are also anticipated to increase approximately 4% year over year in the same period.
Emerson’s expansion initiatives are expected to drive growth. In March 2025, the company completed the acquisition of all outstanding shares of AspenTech’s common stock that it did not previously own. EMR acquired a 55% majority stake in AspenTech in 2022, later increasing its ownership to approximately 57%. AspenTech now operates as a wholly owned subsidiary of Emerson. This acquisition augmented EMR’s automation portfolio and extended its presence into new markets, allowing it to strengthen its capabilities in software-defined control within the industrial automation market.
The company believes in rewarding its shareholders handsomely through dividend payments and share buybacks. In the first six months of 2025, Emerson paid out dividends of $598 million and repurchased common stocks worth $1.12 billion. In November 2024, the company hiked its dividend by 0.5%. Emerson plans to repurchase shares worth $2.3 billion and pay out dividends of $1.2 billion in fiscal 2025.
EMR’s Price Performance
In the past year, the stock has gained 13.5% against the industry’s 12.3% decline.
Image Source: Zacks Investment Research
Headwinds Plaguing EMR
Softness across the Safety & Productivity, Discrete Automation and Test & Measurement businesses is a concern for Emerson. The Safety & Productivity business is witnessing weakness owing to tepid demand for its products across all geographies. The Discrete Automation business continues to struggle due to softness in Asia, the Middle East & Africa, and Europe regions. Weakness in the Europe region is adversely affecting the Test & Measurement business’ sales.
Emerson has considerable exposure to regions outside the United States. Its significant international presence exposes it to political and economic disruptions, all of which can directly affect its profits. Also, the company is exposed to headwinds arising from unfavorable movements in foreign currencies. Adverse foreign currency translation lowered its sales by 1% year over year in the second quarter of fiscal 2025.
Zacks Rank & Stocks to Consider
EMR currently carries a Zacks Rank #3 (Hold). Some better-ranked companies are discussed below:
CCK delivered a trailing four-quarter average earnings surprise of 16.3%. In the past 60 days, the Zacks Consensus Estimate for Crown Holdings’ 2025 earnings has increased 3.8%.
Broadwind, Inc. (BWEN - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 61.1%.
In the past 60 days, the consensus estimate for BWEN’s 2025 earnings has increased 14.3%.
The Gorman-Rupp Company (GRC - Free Report) presently carries a Zacks Rank of 2. It has a trailing four-quarter average earnings surprise of 2.4%.
The Zacks Consensus Estimate for GRC’s 2025 earnings has increased by a penny in the past 60 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Emerson Exhibits Strong Prospects Despite Persisting Headwinds
Key Takeaways
Emerson Electric Co. (EMR - Free Report) is poised to gain from healthy demand across the majority of its end markets. Solid demand in the process and hybrid industries is boosting underlying sales. EMR’s underlying sales increased 2% year over year in the first six months of fiscal 2025 (ended March 2025). The company expects sales in the process and hybrid industry to grow in mid-single digits in the second half of fiscal 2025, driven by strength in the life sciences, energy, liquefied natural gas (LNG) and power end markets.
Strong momentum in the Intelligent Devices and Software and Control segments is driving Emerson’s performance. The Intelligent Devices segment is seeing strength in the Final Control business, fueled by robust demand in power end markets. The Measurement & Analytical business is benefiting from robust growth across the Asia, the Middle East and Africa regions. In the Software & Control segment, solid growth at AspenTech and strength in the power and process end markets are boosting the Control Systems & Software business’ performance.
Given the strength across EMR’s end markets, it has updated its outlook for fiscal 2025 (ending September 2025). Emerson now expects net sales to increase approximately 4% year over year compared with 1.5-3.5% anticipated earlier. Underlying sales are also anticipated to increase approximately 4% year over year in the same period.
Emerson’s expansion initiatives are expected to drive growth. In March 2025, the company completed the acquisition of all outstanding shares of AspenTech’s common stock that it did not previously own. EMR acquired a 55% majority stake in AspenTech in 2022, later increasing its ownership to approximately 57%. AspenTech now operates as a wholly owned subsidiary of Emerson. This acquisition augmented EMR’s automation portfolio and extended its presence into new markets, allowing it to strengthen its capabilities in software-defined control within the industrial automation market.
The company believes in rewarding its shareholders handsomely through dividend payments and share buybacks. In the first six months of 2025, Emerson paid out dividends of $598 million and repurchased common stocks worth $1.12 billion. In November 2024, the company hiked its dividend by 0.5%. Emerson plans to repurchase shares worth $2.3 billion and pay out dividends of $1.2 billion in fiscal 2025.
EMR’s Price Performance
In the past year, the stock has gained 13.5% against the industry’s 12.3% decline.
Image Source: Zacks Investment Research
Headwinds Plaguing EMR
Softness across the Safety & Productivity, Discrete Automation and Test & Measurement businesses is a concern for Emerson. The Safety & Productivity business is witnessing weakness owing to tepid demand for its products across all geographies. The Discrete Automation business continues to struggle due to softness in Asia, the Middle East & Africa, and Europe regions. Weakness in the Europe region is adversely affecting the Test & Measurement business’ sales.
Emerson has considerable exposure to regions outside the United States. Its significant international presence exposes it to political and economic disruptions, all of which can directly affect its profits. Also, the company is exposed to headwinds arising from unfavorable movements in foreign currencies. Adverse foreign currency translation lowered its sales by 1% year over year in the second quarter of fiscal 2025.
Zacks Rank & Stocks to Consider
EMR currently carries a Zacks Rank #3 (Hold). Some better-ranked companies are discussed below:
Crown Holdings, Inc. (CCK - Free Report) currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CCK delivered a trailing four-quarter average earnings surprise of 16.3%. In the past 60 days, the Zacks Consensus Estimate for Crown Holdings’ 2025 earnings has increased 3.8%.
Broadwind, Inc. (BWEN - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 61.1%.
In the past 60 days, the consensus estimate for BWEN’s 2025 earnings has increased 14.3%.
The Gorman-Rupp Company (GRC - Free Report) presently carries a Zacks Rank of 2. It has a trailing four-quarter average earnings surprise of 2.4%.
The Zacks Consensus Estimate for GRC’s 2025 earnings has increased by a penny in the past 60 days.